Novel UL23 and UL30 substitutions in HSV1 and HSV2 viruses related to polymorphism or drug resistance. Novel UL23 and UL30 substitutions in HSV1 and HSV2 viruses related to polymorphism or drug resistance

The emergence of resistant herpes virus infections is a delicate situation to manage in immunocompromised patients, especially in those with hematopoietic stem cells transplant. Reactive diagnostic is thus necessary but data about Herpes simplex virus (HSV) polymorphism and acyclovir (ACV) and foscarnet (FOS) resistance mutations is not exhaustive and can represent a brake for an accurate diagnosis. Currently, next generation sequencing (NGS) is more and more used and has been reported as an added value compared to Sanger sequencing, particularly for the detection of minority subpopulations (Mercier-Darty et al., 2019). Herein, we report not previously described UL23 and UL30 substitutions for both HSV1 and HSV2, identified in immunocompromised patients from hematology departments during the last 6-year of HSV resistance surveillance at a University Hospital.

免疫功能低下患者，尤其是造血干细胞移植受者，其耐药性疱疹病毒感染的临床管理是一项棘手的课题。因此亟需开展反应性诊断，但目前关于单纯疱疹病毒（Herpes simplex virus, HSV）多态性以及阿昔洛韦（acyclovir, ACV）、膦甲酸钠（foscarnet, FOS）耐药突变的相关数据仍不全面，这可能会阻碍精准诊断的实施。当前，下一代测序（next generation sequencing, NGS）的应用愈发广泛，已有研究表明其相较桑格测序（Sanger sequencing）更具应用价值，尤其适用于少数亚群的检测（Mercier-Darty等，2019）。本研究报道了某大学医院近6年疱疹病毒耐药监测期间，于血液科免疫功能低下患者体内检出的、此前尚未被描述过的HSV1与HSV2型UL23及UL30基因替换突变。